Buy Retatrutide — Research-Grade Triple Agonist (HPLC-Verified)

Retatrutide is a 39-amino-acid synthetic peptide engineered as a balanced agonist of three receptors — GLP-1, GIP and glucagon. Compared with single-receptor reference compounds like semaglutide, the addition of glucagon receptor activity is hypothesised to amplify hepatic lipid oxidation and resting energy expenditure in research models. Published phase 2 data has driven a sharp rise in academic and independent-laboratory interest, and supply chain transparency has become a deciding factor when sourcing research material.

Because retatrutide is investigational, supply is fragmented. Regena Peptides ships only material that arrives with a third-party HPLC certificate, an identity confirmation by mass spectrometry, and a clean process-impurities profile. Buyers ordering retatrutide for in-vitro work, ex-vivo preparations or preclinical research see the same COA the lab does.

Each retatrutide batch is independently tested before any vial is released to dispatch. Reverse-phase HPLC quantifies main-peak purity (target ≥99.0%), gradient mass spectrometry confirms the calculated molecular weight, and a Karl Fischer or thermogravimetric measurement reports residual moisture. Aggregated impurity peaks are characterised so researchers know whether minor signals correspond to des-amino byproducts, oxidation products or process residues.

Janoshik Analytical is the most widely recognised independent peptide laboratory in Europe and remains our default third-party verifier for retatrutide. Buyers can download the Janoshik report PDF directly from the lab reports page, cross-referenced by batch number printed on the vial cap.

Lyophilised retatrutide is dispatched as a sterile white powder under nitrogen. Hold the unopened vial at 2–8 °C; freeze at −20 °C only if the vial will not be reconstituted within 8–12 weeks. Reconstitute with bacteriostatic water (0.9% benzyl alcohol) for in-use stability up to 28 days under refrigeration. Sterile water is acceptable for single-day work but should not be used for multi-day storage.

Aim for a working concentration that matches your protocol — most laboratories favour 5 mg/ml or 10 mg/ml stock solutions for ease of microlitre dispensing. Always vortex gently or swirl; never shake aggressively. Aliquot before first freeze to avoid repeat freeze–thaw cycles, which are the single biggest cause of measurable potency loss across long-acting analogues.

Regena dispatches retatrutide from our Costa del Sol logistics base with same- or next-day delivery to Marbella, Málaga, Fuengirola, Mijas, Estepona and the wider Andalucía region. Spain-wide tracked courier service typically arrives in 24–48 hours; cross-border EU shipping to Germany, France, Italy, Portugal, the Netherlands and the Nordics is handled by DHL Express with full track-and-trace.

For research teams importing into the EU, every shipment includes a research-use customs declaration and the matching batch COA so customs handling stays smooth. We do not ship to jurisdictions that prohibit research peptide import — when in doubt the consultations team will confirm before any order is placed.

UK-based researchers receive retatrutide via tracked courier from our European hub. Brexit-era VAT and import handling is included transparently at checkout so there are no surprise customs fees on delivery. Typical UK transit is 2–4 working days; the Regena team can quote DHL Express options for laboratories that need faster handover.

All UK shipments carry the same Janoshik or equivalent third-party COA used for EU orders. If your university or commercial laboratory requires additional paperwork — a Material Safety Data Sheet, a CoO, or a CoC — request it at consultation and the documentation is supplied before dispatch.

Regena supplies US-based research clients with discreet, fully tracked international dispatch. Vials are shipped in temperature-buffered packaging to preserve cold chain across longer transit windows. Buyers receive the same batch COA the European laboratories receive — the only difference is the carrier and the customs paperwork at the destination.

US researchers ordering for in-vitro programmes should confirm institutional purchasing policy before placing an order. Regena material is sold strictly for research use only and is not approved for human consumption in any jurisdiction.

Semaglutide is a single GLP-1 receptor agonist; tirzepatide is a balanced GLP-1/GIP dual agonist; retatrutide adds glucagon receptor activity on top of both incretin arms. In side-by-side preclinical research, retatrutide has produced larger effects on lipid oxidation and resting energy expenditure in animal models than either dual or single agonists — though direct head-to-head human data remains limited.

Researchers building a comparative panel typically stock all three compounds at matched concentrations and rotate them through the same assays. Regena maintains continuous catalogue depth across semaglutide, tirzepatide and retatrutide so panel restocks land from the same supplier with consistent batch documentation.

An honest retatrutide supplier publishes the third-party COA on a per-batch basis and prints the batch number on every vial. Beware suppliers that show a single static COA across all batches, refuse to name their testing laboratory, or quote prices significantly below the cost of independent HPLC and MS verification — those are reliable indicators of unverified or under-tested material.

Regena also publishes its broader quality programme — cold-chain logistics, vial-fill audits, and the contact path for batch-traceability questions. The consultations team will walk a new buyer through the COA, the reconstitution maths and the storage plan before any order is dispatched.